Solid Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Updates

– Patients dosed in Phase 1/2 INSPIRE DUCHENNE trial of SGT-003 for the treatment of Duchenne muscular dystrophy (Duchenne); Dosing was well tolerated in all patients with initial data expected Q4 2024 – – Solid plans to expand patient dosing with additional clinical trial sites in the U.S., Canada and Europe and plans accelerated production of multiple GMP batches of SGT-003 to support trial expansion – – Targeting the submission of 3-4 INDs by the end of 2026, strategically selecting cardiac and neuromusc ...